Tìm theo
Rizatriptan
Các tên gọi khác (7 ) :
  • MK 462 free base
  • N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine
  • N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine
  • Risatriptan
  • Rizatriptan benzoat
  • Rizatriptan benzoate
  • Rizatriptanum
serotonin antagonists, serotonin receptor agonists, anti migraine agents
Thuốc Gốc
Small Molecule
CAS: 145202-66-0
ATC: N02CC04
ĐG : Catalent Pharma Solutions , http://www.catalent.com
CTHH: C15H19N5
PTK: 269.3449
Rizatriptan is a triptan drug used for the treatment of migraine headaches. It is a selective 5-hydroxytryptamine1 receptor subtype agonist.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C15H19N5
Phân tử khối
269.3449
Monoisotopic mass
269.164045633
InChI
InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3
InChI Key
InChIKey=ULFRLSNUDGIQQP-UHFFFAOYSA-N
IUPAC Name
dimethyl({2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethyl})amine
Traditional IUPAC Name
rizatriptan
SMILES
CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2
Độ tan chảy
178-180 °C
Độ hòa tan
42 mg/mL (for free base)
logP
1.4
logS
-2.9
pKa (strongest acidic)
17.24
pKa (Strongest Basic)
9.56
PSA
49.74 Å2
Refractivity
93.13 m3·mol-1
Polarizability
30 Å3
Rotatable Bond Count
5
H Bond Acceptor Count
3
H Bond Donor Count
1
Physiological Charge
1
Number of Rings
3
Bioavailability
1
Rule of Five
true
Ghose Filter
true
Dược Lực Học : Rizatriptan is a selective agonist of serotonin (5-hydroxytryptamine; 5-HT) type 1B and 1D receptors. It is structurally and pharmacologically related to other selective 5-HT1B/1D receptor agonists and has only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Rizatriptan also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Rizatriptan in humans.
Cơ Chế Tác Dụng : Rizatriptan is a triptan drug used for the treatment of migraine headaches. It is a selective 5-hydroxytryptamine1 receptor subtype agonist. Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism.
Dược Động Học :
▧ Absorption :
Rapid following oral administration. Bioavailability is 45%. Food has no effect on the bioavailability of rizatriptan. However, administering rizatriptan with food will delay by 1 hour the time to reach peak plasma concentration. The rate of absorption is not affected by the presence of a migraine attack.
▧ Volume of Distribution :
* 140 L [male] * 110 L [female]
▧ Protein binding :
14%
▧ Metabolism :
Rizatriptan is metabolized by monoamine oxidase A isoenzyme (MAO-A) to an inactive indole acetic acid metabolite. In addition, several other inactive metabolites are formed. An active metabolite, N-monodesmethyl-rizatriptan, with pharmacological activity similar to that of the parent compound has been identified in small concentrations (14%) in the plasma.
▧ Route of Elimination :
Approximately 14% of an oral dose is excreted in urine as unchanged rizatriptan while 51% is excreted as indole acetic acid metabolite, indicating substantial first pass metabolism.
▧ Half Life :
2-3 hours
Độc Tính : Symptoms of overdose include dizziness, fainting, heart and blood vessel problems, high blood pressure, loss of bowel and bladder control, slow heartbeat, and vomiting.
Chỉ Định : For treatment of acute migraine attacks with or without aura.
Tương Tác Thuốc :
  • Citalopram Increased risk of CNS adverse effects
  • Desvenlafaxine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
  • Dihydroergotamine Possible severe and prolonged vasoconstriction
  • Ergotamine Possible severe and prolonged vasoconstriction
  • Escitalopram Increased risk of CNS adverse effects
  • Fluoxetine Increased risk of CNS adverse effects
  • Fluvoxamine Increased risk of CNS adverse effects
  • Isocarboxazid The MAO inhibitor, isocarboxazid, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated.
  • Methysergide Possible severe and prolonged vasoconstriction
  • Moclobemide The MAO inhibitor, moclobemide, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated.
  • Nefazodone Increased risk of CNS adverse effects
  • Paroxetine Increased risk of CNS adverse effects
  • Phenelzine The MAO inhibitor, phenelzine, may decrease the metabolism and clearance of the serotonin 5-HT receptor agonist, rizatriptan. Concomitant therapy is contraindicated.
  • Propranolol Propranolol increases the effect and toxicity of rizatriptan
  • Tramadol Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
  • Tranylcypromine The MAO inhibitor, Tranylcypromine, may reduce the metabolism and clearance of the serotonin 5-HT1D receptor agonist, Rizatriptan. Risk of serotonin syndrome and Rizatriptan toxicity. Concomitant therapy should be avoided.
  • Trazodone Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
  • Trimipramine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
  • Venlafaxine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
  • Zolmitriptan Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and rizatriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
Liều Lượng & Cách Dùng : Tablet - Oral
Wafer - Oral
Dữ Kiện Thương Mại
Giá thị trường
Nhà Sản Xuất
  • Công ty :
    Sản phẩm biệt dược : Maxalt
  • Công ty :
    Sản phẩm biệt dược : Maxalt MLT
  • Công ty :
    Sản phẩm biệt dược : Maxalt-MLT
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00953
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=5078
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46506557
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D00675
ChemSpider
http://www.chemspider.com/Chemical-Structure.4900.html
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/0006-0266-12
PharmGKB
http://www.pharmgkb.org/drug/PA451264
Wikipedia
http://en.wikipedia.org/wiki/Rizatriptan
RxList
http://www.rxlist.com/cgi/generic2/rizatrip.htm
PDRhealth
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/max1248.shtml
Drugs.com
http://www.drugs.com/cdi/rizatriptan.html
... loading
... loading